COVID-19 vaccine: China trials mixing from CanSinoBIO and Zhifei Longcom
Chinese researchers are testing mixing two COVID-19 vaccines developed by CanSino Biologics and a unit of Chongqing Zhifei Biological Products as a way of further boosting vaccine efficacy.
The director of the Chinese Center for Disease Control and Prevention (CCDC), Gao Fu, earlier this month said the country was formally considering giving people COVID-19 vaccines developed with different technologies.
A trial expected to involve 120 participants will test the safety and ability to trigger immune response of a dose of CanSinoBIO’s Ad5-nCoV treatment, followed by a dose of ZF2001 from Anhui Zhifei Longcom Biopharmaceutical, at 28-day or 56-day interval.
CanSinoBIO said interim data from overseas Phase III clinical trials showed its Ad5-nCoV vaccine was 68.83% effective at preventing symptomatic COVID-19 disease two weeks after one injection, while the rate fell to 65.28% four weeks after one shot.
The researchers are also running trials for two dose based vaccination of Ad5-nCoV, as well as an inhalation version of the vaccine.
No efficacy readings has been made available from Phase III trials for Zhifei Longcom’s ZF2001 vaccine, which requires three injections when used on its own.
CanSinoBIO and Chongqing Zhifei Biological Products were not immediately available for comment.
Both vaccines are included in China’s mass vaccination drive.
READ ALSO: China considers mixing vaccines to increase its Efficacy
Kamila/Reuters
